Welcome to Paid Research Studies


Browse Locations ... United States» ... Massachusetts» ... Cambridge






  • Conditions:   Vasomotor Symptoms;   Cardiovascular Health
    Intervention:   Drug: Gabapentin
    Sponsors:   Massachusetts General Hospital;   Brigham and Women's Hospital;   Spaulding Rehabilitation Hospital
    Recruiting - verified July 2014

  • Conditions:   Schizophrenia;   Schizoaffective Disorder;   Bipolar Disorder;   Depression
    Interventions:   Behavioral: CBHH+AT;   Behavioral: CBHH+SMT;   Behavioral: CBHH
    Sponsors:   Dartmouth-Hitchcock Medical Center;   National Institute of Mental Health (NIMH)
    Not yet recruiting - verified July 2014

  • Condition:   Uveitis
    Interventions:   Drug: Sarilumab SAR153191/REGN88;   Drug: Prednisone;   Drug: Methotrexate;   Drug: Folic/folinic acid;   Other: Sarilumab (SAR153191/REGN88) placebo
    Sponsors:   Sanofi;   Regeneron Pharmaceuticals
    Recruiting - verified July 2014

  • Condition:   Healthy Adults
    Interventions:   Drug: Syntocinon Nasal Spray, 40IU;   Drug: Syntocinon Placebo Formulation, 40IU
    Sponsors:   Stony Brook University;   Martinos Center for Biomedical Imaging
    Recruiting - verified July 2014

  • Condition:   Uveitis
    Interventions:   Drug: Placebo;   Drug: Dose 1 gevokizumab;   Drug: Dose 2 gevokizumab
    Sponsors:   XOMA (US) LLC;   Institut de Recherches Internationales Servier
    Recruiting - verified July 2014

  • Condition:   Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases
    Intervention:  
    Sponsors:   Genentech;   Accord Healthcare, Inc.;   Sandoz Inc.;   Apotex Corporation;   Novartis Pharmaceuticals;   Pfizer;   Mylan Pharmaceuticals;   Teva Pharmaceuticals USA;   Alkem Laboratories Ltd;   Roxane Laboratories;   Vintage Pharmaceuticals, LLC
    Recruiting - verified July 2014

  • Conditions:   Posterior Uveitis;   Intermediate Uveitis;   Panuveitis
    Interventions:   Drug: FAI insert;   Drug: Sham injection
    Sponsor:   pSivida Corp.
    Recruiting - verified July 2014

  • Condition:   Uveitis
    Interventions:   Drug: Placebo;   Drug: Dose 1 gevokizumab;   Drug: Dose 2 gevokizumab
    Sponsors:   XOMA (US) LLC;   Institut de Recherches Internationales Servier
    Recruiting - verified July 2014

  • Condition:   Periodontal Disease
    Intervention:   Other: Periodontal therapy
    Sponsors:   The Forsyth Institute;   National Institute of Dental and Craniofacial Research (NIDCR);   New York University School of Medicine;   State University of New York at Buffalo;   University of Michigan;   Southern Illinois University
    Recruiting - verified January 2014

  • Condition:   Obsessive-compulsive Disorder
    Interventions:   Behavioral: Cognitive-behavioral therapy;   Drug: d-cycloserine;   Drug: Pill placebo
    Sponsors:   University of South Florida;   Massachusetts General Hospital
    Recruiting - verified July 2014

  • Conditions:   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: docetaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Drug: paclitaxel;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Condition:   Uveitis
    Interventions:   Drug: adalimumab;   Drug: prednisone;   Drug: prednisone;   Drug: adalimumab placebo
    Sponsors:   AbbVie;   AbbVie (prior sponsor, Abbott)
    Recruiting - verified July 2014

  • Conditions:   Non-Small Cell Lung Cancer;   Anemia;   Cancer;   Lung Cancer
    Interventions:   Drug: darbepoetin alfa 500 mcg Q3W;   Drug: placebo
    Sponsor:   Amgen
    Recruiting - verified July 2014